Abstract
The persistence of the COVID-19 pandemic demands a dramatic increase in testing efficiency. Testing pooled samples for SARS-CoV-2 could meet this need; however, the sensitivity of RT-qPCR, the gold standard, significantly decreases with an increasing number of samples pooled. Here, we introduce DIVER, a method that quantifies intact virus and is robust to sample dilution. DIVER first tags viral particles with exogeneous oligonucleotides, then captures the tagged particles on ACE2-functionalized beads, and finally quantifies the oligonucleotide tags using qPCR. Using spike-presenting liposomes and Spike-pseudotyped lentivirus as SARS-CoV-2 models, we show that DIVER can detect 1×105 liposomes and 100 pfu lentivirus and can successfully identify positive samples in pooling experiments. Overall, DIVER is well-positioned for efficient sample pooling and expanded community surveillance.
Competing Interest Statement
T.R.C., M.K, and L.L.S. are inventors on a U.S. patent application (PCT/US20/62957) submitted by the University of California involving the method to detect via qPCR lipid bilayer nanoparticles labeled with cholesterol-modified oligonucleotides.
Funding Statement
This work was supported in part by CITRIS COVID-19 Response Seed Funding (L.L.S.), University of California Cancer Research Coordinating Committee Fellowship (T.R.C.), NIH/NCI 1F32CA243354-01 (M.K.), CZ Biohub Intercampus Research Award (L.C.), and a generous gift from Margaret and Michael Checca (L.L.S.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No human or animal samples or subjects were used in this research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data needed to evaluate the conclusions in this paper are available in the manuscript or supplementary materials.
